Vifor Fresenius Medical Care Renal Pharma and Relypsa enter into partnership to commercialize Patiromer FOS in Europe and additional territories
August 11, 2015 01:09 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ST....
Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe
May 28, 2015 01:11 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Galenica...
Velphoro® a reçu l'autorisation de mise sur le marché de Swissmedic pour le traitement de l'hyperphosphatémie chez les patients adultes atteints d'insuffisance rénale chronique et placés sous dialyse
January 27, 2015 01:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Velphoro® (oxyhydroxyde de fer (III)...
Velphoro® erhält die Swissmedic Zulassung zur Behandlung der Hyperphosphatämie bei dialysepflichtigen erwachsenen Patienten mit chronischer Niereninsuffizienz
January 27, 2015 01:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Velphoro® (Polynukleares...
Vifor Pharma appoints heads of International Business Operations and Global Marketing
September 16, 2014 01:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Vifor...
CONFIRM-HF study demonstrates that Injectafer(r) (Ferinject(r)) improves exercise capacity in patients with chronic heart failure
September 02, 2014 06:52 ET
|
Vifor Pharma Ltd.
Glattbrugg, Switzerland, Sept. 2, 2014 (GLOBE NEWSWIRE) -- The CONFIRM-HF study was designed to compare the efficacy and safety of iron therapy with Injectafer® (US brand name of Ferinject®,...
CONFIRM-HF study demonstrates that Injectafer® (Ferinject®) improves exercise capacity in patients with chronic heart failure
September 02, 2014 06:50 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
The...
CONFIRM-HF study demonstrates that Ferinject® improves exercise capacity in patients with chronic heart failure
September 01, 2014 01:16 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
The...
Velphoro® receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis
August 27, 2014 01:10 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Velphoro®...
Velphoro® recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysis
June 27, 2014 08:57 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Velphoro®...